Search
Aquestive Therapeutics Inc
AQSTAdd to Watchlist
4.180USD
-0.060-1.42%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
519.51MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.42%
5 Days
-4.78%
1 Month
+0.97%
6 Months
-35.19%
Year to Date
-35.29%
1 Year
+12.37%
Key Figures
4.230Open
4.355High
1.73MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.39%Turnover Ratio
4.240Prev. Close
4.145Low
5.34MTurnover
LossP/E Static
-15.26P/B
0.00%Div Yield TTM
-56.63%ROA
7.55052wk High
0.96Volume Ratio
-44.14MNet Profit
124.28MShares
-0.6092EPS TTM
1.46Beta
--ROE
2.64052wk Low
4.95%Amplitude
75.99%Gross Margin
519.51MMarket Cap
0.66Reward/Risk
3.64%Risk Rate
TradingKey Stock Score of Aquestive Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Aquestive Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 63 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.89.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Aquestive Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Aquestive Therapeutics Inc Highlights
StrengthsRisks
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Growing
The company is in a growing phase, with the latest annual income totaling USD 44.55M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 44.55M.
Fairly Valued
The company’s latest PE is -6.86, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 74.94M shares, decreasing 9.08% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 912.50K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.01.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
8.889
Target Price
+109.64%
Upside Space
Aquestive Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Aquestive Therapeutics Inc Info
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Ticker SymbolAQST
CompanyAquestive Therapeutics Inc
CEOBarber (Daniel R)
Websitehttps://aquestive.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Aquestive Therapeutics Inc (AQST)?
The current price of Aquestive Therapeutics Inc (AQST) is 4.18.
What is the symbol of Aquestive Therapeutics Inc?
The ticker symbol of Aquestive Therapeutics Inc is AQST.
What is the 52-week high of Aquestive Therapeutics Inc?
The 52-week high of Aquestive Therapeutics Inc is 7.55.
What is the 52-week low of Aquestive Therapeutics Inc?
The 52-week low of Aquestive Therapeutics Inc is 2.64.
What is the market capitalization of Aquestive Therapeutics Inc?
The market capitalization of Aquestive Therapeutics Inc is 519.51M.
Is Aquestive Therapeutics Inc (AQST) currently rated as Buy, Hold, or Sell?
According to analysts, Aquestive Therapeutics Inc (AQST) has an overall rating of Buy, with a price target of 8.89.
What is the Earnings Per Share (EPS TTM) of Aquestive Therapeutics Inc (AQST)?
The Earnings Per Share (EPS TTM) of Aquestive Therapeutics Inc (AQST) is -0.78.